HKD 3.58
(-0.56%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -77.14 Million USD | 20.1% |
2022 | -96.54 Million USD | 55.22% |
2021 | -215.59 Million USD | -456.41% |
2020 | -38.74 Million USD | -132.64% |
2019 | -16.65 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 FY | -77.14 Million USD | 20.1% |
2023 Q1 | - HKD | 0.0% |
2023 Q2 | - HKD | 0.0% |
2023 Q3 | - HKD | 0.0% |
2022 FY | -96.54 Million USD | 55.22% |
2022 Q4 | - HKD | 0.0% |
2022 Q3 | - HKD | 0.0% |
2021 Q3 | -16.4 Million USD | 0.0% |
2021 Q4 | -165.79 Million USD | -910.89% |
2021 FY | -215.59 Million USD | -456.41% |
2020 Q4 | -5.79 Million USD | 0.0% |
2020 FY | -38.74 Million USD | -132.64% |
2019 FY | -16.65 Million USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | 213.838% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 108.591% |